PBM margin reset challenges the Cigna cleanup story
- Cigna is becoming a more focused employer health and pharmacy services company after selling its Medicare assets.
- Specialty and Care Services adjusted earnings grew 22% in Q2 2026, helped by fast biosimilar adoption.
- Pharmacy Benefit Services pretax adjusted earnings fell 27% in Q2 2026 as pricing reset to the new Signature model.
- Cigna Healthcare saw its Q2 2026 medical care ratio jump to 84.5%, confirming Q1 strength was just a timing anomaly.
- GLP-1 costs have reached a point where Cigna discontinued coverage for weight management within its own employee plan.
A cleanup with a margin problem
Cigna has a clear bull story. It is cutting away messier businesses, including Medicare Advantage and individual exchange plans, and leaning into employer health plans, pharmacy services, specialty drugs, and care services. That could make the company simpler and more focused. The divestiture of the Medicare Advantage business to HCSC is now complete.
The strongest current proof point is Specialty and Care Services inside Evernorth. In Q2 2026, that business grew pretax adjusted earnings 22%, helped by biosimilars and GLP-1 management. Cigna is also expanding Health System Services, which manages specialty pharmacies for hospitals, providing a new avenue for growth.
The bear case is painful right now. Pharmacy Benefit Services pretax adjusted earnings fell 27% in Q2 2026. The drop came from large client renewals that reset pricing lower and from investment in Signature, Cigna's rebate-free pharmacy model.
Cigna Healthcare also showed signs of stress. Its Q2 2026 medical care ratio, the share of premiums spent on medical claims, increased to 84.5%. This jump confirmed that earlier strength was driven by timing and weather anomalies, meaning medical costs remain high. Furthermore, abuses of the No Surprises Act independent dispute resolution process are compounding cost pressures.
Two engines under different pressures
Cigna makes money through two main platforms. Evernorth Health Services sells pharmacy benefit management, specialty pharmacy, drug distribution, virtual care, behavioral health, and other care services. Cigna Healthcare sells medical insurance and health plan administration to employers, individuals, and international customers.
In Pharmacy Benefit Services, Cigna earns from managing drug benefits, pharmacy networks, claims, and related services. This model is changing fast. Signature is designed to be more transparent and rebate-free, but the transition is actively cutting margins.
Specialty and Care Services is the cleaner growth engine. Accredo specialty pharmacy, specialty drug distribution, biosimilar adoption, and new health system management services are helping profit grow even while the older pharmacy piece weakens. However, GLP-1 volume growth is moderating, and costs are so high that Cigna dropped GLP-1 weight management coverage for its own employees.
Cigna Healthcare earns premiums on insured plans and fees on administrative services only plans, where employers carry the claims risk. The company is focusing on employer markets, plans to exit individual exchanges by the end of 2026, and is reviewing EviCore for a possible sale or partnership.
What Cigna sells
Pharmacy Benefit Services
This is Cigna's traditional PBM business, managing drug benefits, networks, and claims. Earnings fell sharply in Q2 2026 as pricing reset and Signature investment continued.
Signature rebate-free pharmacy model
Signature is Cigna's push toward a more transparent pharmacy service without traditional rebate economics. It is pressuring profit during the transition.
Specialty pharmacy and drug distribution
Accredo and related specialty services handle complex, high-cost drugs. This area is benefiting heavily from biosimilars and GLP-1 management.
Health System Services
Shields Health Solutions and related brands manage specialty pharmacies directly for hospitals, capturing a growing market.
Care services and behavioral health
These services help employers and health plans manage care and access. EviCore, a benefits management asset, is currently under strategic review.
U.S. employer health plans
Cigna sells insured and administrative services only health plans to employers. This is the main focus of Cigna Healthcare after the Medicare sale.
International Health
Cigna offers medical, dental, life, and related coverage outside the U.S. It is smaller than the U.S. and Evernorth businesses, but adds geographic diversification.
Where Q1 2026 revenue sat
The mix uses Q1 2026 adjusted revenues before Corporate eliminations: Pharmacy Benefit Services $33,002 million, Specialty and Care Services $25,440 million, Cigna Healthcare $11,477 million, and Other Operations $120 million.
What could break the case
PBM margin floor is lower than hoped
High impact · High oddsPharmacy Benefit Services pretax adjusted earnings fell 27% in Q2 2026. The pressure came from large client pricing resets and investment in Signature. If that margin reset lasts longer than expected, Evernorth may struggle to act as Cigna's dependable growth engine.
Medical costs reappear after a strong start
High impact · High oddsCigna Healthcare reported an 84.5% medical care ratio in Q2 2026, rising 130 basis points year over year. This confirms that Q1 strength was a fluke. Additionally, independent dispute resolution volume is creating unsustainable cost pressure.
PBM regulation changes the profit pool
High impact · High oddsThe Consolidated Appropriations Act, 2026 requires PBMs to pass through 100% of rebates for ERISA plans starting in August 2028. Cigna is moving first with Signature, but a required industry reset can still reduce overall earnings power.
GLP-1 costs compress margins
Medium impact · Medium oddsThe cost of GLP-1 weight loss drugs has become incredibly acute. Cigna discontinued financial support for GLP-1 drugs for weight management within its own employee health plan, showing the intense pressure these drugs put on employer budgets.
Portfolio cleanup creates gaps
Medium impact · Medium oddsCigna has sold Medicare assets and plans to exit individual exchanges by the end of 2026. That can improve focus, but it also removes revenue. The EviCore strategic review adds another moving piece to the puzzle.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 16, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Healthcare Plans companies
Companies near Cigna Corporation in Finn's Healthcare Plans industry ranking.
